Lantheus (LNTH) Holdings completed the previously announced sale of its single photon emission computed tomography business to SHINE Technologies. Under the terms of the agreement, SHINE has acquired Lantheus’ SPECT business, including its diagnostic agents, the portion of the North Billerica, Massachusetts campus that manufactures Lantheus’ SPECT products, and the SPECT-related Canadian operations. With the SPECT divestiture finalized, Lantheus will focus on its growing commercial portfolio of PET radiodiagnostics and microbubbles, while also advancing its pipeline of radiopharmaceuticals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LNTH:
- Lifeward chairman Joseph Turk to depart, Lantheus CFO Bob Marshall to succeed
- Lantheus price target raised to $82 from $80 at Truist
- Lantheus price target raised to $72 from $60 at Mizuho
- Lantheus upgraded to Buy at Truist on profit re-acceleration prospects
- Lantheus upgraded to Buy from Hold at Truist